Abstract: A method of recycling fibers from post-consumer nylon fabrics is performed as follows. Post-consumer nylon textiles are crushed to obtain crushed textiles, which are fed to a two-stage screw machine, and transported to a compression zone, a melting zone, and a metering zone in sequence. Then the crushed textiles are subjected to water cooling, air cooling, granulation and drying to obtain nylon fabric chips, which are subjected to secondary granulation. The nylon fabric chips and a nylon-6 masterbatch are fed into a composite core screw and a skin screw to obtain a mixed melt, which is fed into a spinning box and compounded to obtain a coated filament bundle. The coated filament bundle is ejected for monomer suction, and subjected to primary cooling by lateral blowing, cluster oiling, secondary cooling, stretched shaping and winding to obtain recycled fibers.

Abstract: The invention provides substituted pyrrolo[1,2-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

Abstract: A fraudulent transaction detection method comprises: performing feature mapping processing on each of a plurality of transaction data to generate corresponding feature vectors; converting the feature vectors of a transaction to be detected into integrated feature vectors based on a first self-learning model; respectively converting the feature vectors respectively of at least one time sequence transaction into time sequence feature vectors based on a second self-learning model; combining the integrated feature vectors and each of the time sequence feature vectors corresponding to each of the time sequence transactions to form depth feature vectors; classifying the depth feature vectors based on a third self-learning model to determine whether the transaction to be detected is a normal transaction or a fraudulent transaction.

Abstract: The invention provides substituted pyrrolo[1,2-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

Abstract: Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.

Abstract: A fraudulent transaction detection method comprises: performing feature mapping processing on each of a plurality of transaction data to generate corresponding feature vectors; converting the feature vectors of a transaction to be detected into integrated feature vectors based on a first self-learning model; respectively converting the feature vectors respectively of at least one time sequence transaction into time sequence feature vectors based on a second self-learning model; combining the integrated feature vectors and each of the time sequence feature vectors corresponding to each of the time sequence transactions to form depth feature vectors; classifying the depth feature vectors based on a third self-learning model to determine whether the transaction to be detected is a normal transaction or a fraudulent transaction.

Abstract: Disclosed are new small molecules having a pyrrolopyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may be utilized to generate activated glucocerebrosidase. The activated glucocerebrosidase thusly generated can be administered in enzyme replacement therapy and/or utilized in screening assays for new small molecules that bind to the activated glucocerebrosidase and/or modulate the activity of the activated glucocerebrosidase.

Abstract: The present invention relates to an off-line PIN authentication and an off-line PIN authentication system. The method comprises: inputting an off-line PIN1 to a POS terminal, the POS terminal generating a dynamic challenge code, and transmitting the dynamic challenge code and the off-line PIN1 to a card application; the card application verifying the first off-line PIN1 and the second off-line PIN2 are consistent with each other or not; if consistent, a digital signature being made on the first off-line PIN1 and the second off-line PIN2 to return signature data and a success status code to the POS terminal; the POS terminal verifying the signature data in case of receiving the success status code, and starting the subsequent transaction procedure if the signature data is verified successfully. According to the present invention, it not only can realize the verification of the IC card to the off-line PIN, but also can realize the verification of the terminal to the off-line PIN.

Abstract: The invention provides substituted pyrrolo[1,2-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

Abstract: Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.

Abstract: Disclosed are new small molecules having a pyrrolopyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, includin neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may be utilized to generate activated glucocerebrosidase. The activated glucocerebrosidase thusly generated can be administered in enzyme replacement therapy and/or utilized in screening assays for new small molecules that bind to the activated glucocerebrosidase and/or modulate the activity of the activated glucocerebrosidase.

Abstract: The invention provides substituted pyrrolo[1,2-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

Abstract: Disclosed are new small molecules having a 4-methylpyrrolo[1,2-a]pyrimidine-8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.

Abstract: Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.

Abstract: A dual-mode rapidly-passing type moving target radiation inspection system comprises a radiation source, a collimator, sensor units, a control module, a radiation detector and a radiation imaging device, wherein the sensor units are used for identifying the type of a moving target and monitoring the position of the moving target in an inspection channel; the control module is used for controlling the radiation source to emit rays in a preset working mode on the basis of the type and the position of the moving target; the preset working mode corresponds to the type of the moving target, and the rays emitted by the radiation source in different working modes differ in dosage rate. Also disclosed is a dual-mode rapidly-passing type moving target radiation inspection method. The inspection system and method described above are capable of radiation inspection of the entire moving targets such as vehicles.

Abstract: Disclosed are new small molecules having a 4-methylpyrrrolo[1,2-a]pyrimidine-8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.

Abstract: Disclosed are new small molecules having a 4-methylpyrrrolo[1,2-a]pyrimidine-8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.

Abstract: The invention provides heterobicyclic pyrimidinone compounds such as thiazolo[3,2-a]pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary heterobicyclic pyrimidinone compounds described herein include 5-oxo-2,3-dihydro-5H-hiazolo[3,2-a]pyrimidine-6-carboxamide compounds.

Abstract: Disclosed are new small molecules having a 4-methylpyrrrolo[1,2-a]pyrimidine-8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.

Abstract: Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.